We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toSignal-Management-Separating-Needles-From-Haystacks

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Signal Management: Separating Needles From Haystacks

    Session Chair(s)
      William  Gregory, PhD

      William Gregory, PhD

      • Safety and Risk Management
      • Pfizer Inc, United States
    The session will discuss signal management throughout the lifecycle and how to transition from the pre-approval to the post approval setting. In the post-approval setting, we will concentrate on signal management requirements in EudraVigilance and provide some examples of how companies are addressing the requirements.
    The speakers have broad experience and represent the perspectives of CROs, large pharma and small biotech companies.
    Learning Objective : Understand what are the key elements to set the foundation for an unique signal management process throughout the lifecycle stage of a product. Understand how the main parameters influencing signal management evolve in both settings as a tool for signal management decision making.
      Uwe  Trinks, DrSc, PhD

      Experiences with the EVDAS Requirements

      Uwe Trinks, DrSc, PhD

      • Partner and Director
      • Foresight Group, An IQVIA Company, United States
      Rosa A. Piccirillo, MD

      From Clinical Trial to Post-Marketing Signal Management: A Continuum

      Rosa A. Piccirillo, MD

      • Senior Director and Global Head, Medical Safety, Core Safety Services
      • IQVIA, United States
      Mick  Foy

      Major Issues With the New Eudravigilance System (EVDAS) That Were Outlined Within the Recent Q&A Document Published by EMA

      Mick Foy

      • Head of Pharmacovigilance Strategy, Vigilance Intelligence and Research Group
      • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom